Nonprofit drugs as the salvation of the world's healthcare systems: the case of Antabuse (disulfiram)

被引:100
作者
Cvek, Boris [1 ]
机构
[1] Palacky Univ, Dept Cell Biol & Genet, Olomouc 78371, Czech Republic
关键词
BREAST-CANCER; VISCERAL LEISHMANIASIS; DIETHYLDITHIOCARBAMATE THERAPY; INHIBITION; PROTEASOME; DITIOCARB; PATIENT;
D O I
10.1016/j.drudis.2011.12.010
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effort to repurpose old drugs for new uses is not sufficient; even drugs that have been used clinically for decades must undergo expensive clinical trials. This process requires the pharmaceutical industry to fund the repatenting of old drugs. Because inexpensive drugs are necessary for people around the world, attempts should be made to develop nonprofit drugs through clinical trials of generic drugs that are funded by governments and charities. Evidence supports the use the old anti-alcoholic drug Antabuse as a new nonprofit drug for cancer.
引用
收藏
页码:409 / 412
页数:4
相关论文
共 44 条
[11]   Antabuse repurposing: we need more knowledge and wide international support [J].
Cvek, Boris .
INTERNATIONAL JOURNAL OF CANCER, 2011, 129 (05) :1286-1287
[12]   Antabuse (disulfiram) as a pilot case of nonprofit drug [J].
Cvek, Boris .
INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (10) :2486-2486
[13]   Failure of Ditiocarb (Diethyldithiocarbamate) Therapy: Was Diet the Reason? [J].
Cvek, Boris .
CURRENT HIV RESEARCH, 2009, 7 (03) :254-254
[14]   Paromomycin [J].
Davidson, Robert N. ;
den Boer, Margriet ;
Ritmeijer, Koert .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2009, 103 (07) :653-660
[15]   Drug repurposing and adverse event prediction using high-throughput literature analysis [J].
Deftereos, Spyros N. ;
Andronis, Christos ;
Friedla, Ellen J. ;
Persidis, Aris ;
Persidis, Andreas .
WILEY INTERDISCIPLINARY REVIEWS-SYSTEMS BIOLOGY AND MEDICINE, 2011, 3 (03) :323-334
[16]  
DiMasi J.A., 2003, J HLTH EC, V22, P185
[17]   SODIUM DITIOCARB AS ADJUVANT IMMUNOTHERAPY FOR HIGH-RISK BREAST-CANCER - A RANDOMIZED STUDY [J].
DUFOUR, P ;
LANG, JM ;
GIRON, C ;
DUCLOS, B ;
HAEHNEL, P ;
JAECK, D ;
JUNG, JM ;
OBERLING, F .
BIOTHERAPY, 1993, 6 (01) :9-12
[18]   THE ACTIONS AND METABOLIC-FATE OF DISULFIRAM [J].
ENEANYA, DI ;
BIANCHINE, JR ;
DURAN, DO ;
ANDRESEN, BD .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1981, 21 :575-596
[19]   How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question [J].
Fojo, Tito ;
Grady, Christine .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (15) :1044-1048
[20]   Are Patents Impeding Medical Care and Innovation? [J].
Gold, E. Richard ;
Kaplan, Warren ;
Orbinski, James ;
Harland-Logan, Sarah ;
N-Marandi, Sevil .
PLOS MEDICINE, 2010, 7 (01)